https://www.selleckchem.com/pr....oducts/mivebresib-ab
A total of 59 of 69 (74%) of patients received pulmonary arterial hypertension (PAH)-specific therapies. Six patients died after liver transplantation (in 3 death was related to PAH-related complications). Most of the patients in this cohort of PoPH patients were considered unsuitable for liver transplantation for a variety of reasons. Advanced healthcare directives were available in only 28% of patients. Most patients with PoPH died because of complications of their liver disease. PAH directly or indirectly contributed to d